Business Wire

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Share

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1

"The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues.

As the first ready-to-use neurotoxin in Europe, Alluzience® is fit for the needs of today; it will allow me to consistently optimize results and deliver patient satisfaction with more precision. Most importantly, it will help people to feel confident in themselves again.”
Dr Joanna Czuwara, MD, PhD, Associate Professor, Department of Dermatology, Warsaw Medical University, Poland

As people age, the skin and underlying muscles play a significant role in the emergence of noticeable lines and folds, including glabellar lines between the eyebrows.2 Clostridium botulinum toxin type A (BoNT-A), the active ingredient in Alluzience®, is often used to smooth facial lines including glabellar lines.2 All currently approved BoNT-A products (or formulations) in Europe come in powder form and require reconstitution with sodium chloride before use.2 The ready-to-use liquid formulation of Alluzience® avoids any calculations and allows for more precision, meaning it has the potential to improve safety and dosing accuracy compared with powder form BoNT-A preparations.2 Alluzience® was developed using novel production technologies meaning it is free from human and animal-derived proteins such as human serum albumin and lactose.1

The European Marketing Authorization Application of Alluzience® is based on pooled data from two pivotal trials of 372 patients with moderate to severe glabellar lines who were treated with either Alluzience® (n=250) or placebo (n=122). These data demonstrated that >50% of patients reported an effect within two to three days, including 23% of patients within one day.1 An effect was demonstrated for up to six months after injection with Alluzience®.1 The responder rate at day 29 was significantly higher for patients treated with Alluzience® compared to placebo (primary endpoint) (p<0.0001).1

Additionally, patients’ level of satisfaction one month following injection showed that 85.2% of the patients receiving Alluzience® were either satisfied or very satisfied compared to 9% for placebo patients.1 The majority of adverse reactions reported with Alluzience® in clinical trials were of mild to moderate intensity and reversible.1 The most frequently reported adverse reactions were headache and injection site reactions.1

"At Galderma we pride ourselves on developing innovative products that meet today’s needs, which is underpinned by our longstanding knowledge and heritage in dermatology. We know how advantageous it is for doctors to have access to a ready-to-use liquid formulation in Alluzience®. It’s for this reason that today's news is an important milestone for both patients and healthcare professionals.”
Alexandre Brennan - Head, Global Business Unit for Aesthetics

About Galderma

Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story.

For more information: www.galderma.com.

About Alluzience® (liquid botulinum toxin type A)

Alluzience® (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience® should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.1 Dosing and treatment intervals depend on assessment of the individual patient’s response.1 The treatment interval should be no more frequent than every three months.1 For more information, please see the Summary of Product Characteristics.1

Alluzience® is a product under license from Ipsen. Alluzience® is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience® in the approved indication in Europe (excluding Czech Republic, Slovakia, Greece, Lithuania, Estonia, Latvia, Hungary).


1 Alluzience Summary of Product Characteristics.
2 Ascher B, Rzany B, Kestemont P, et al. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo Controlled Study of a Single Treatment, Ready-to Use Toxin for Moderate-to-Severe Glabellar Lines. Aesthet Surg J. 2020;40(1):93–104.

Job code: GL-ALZ-2100026
Date of preparation: June 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Lauren Starr, Head of Franchise Communications at Galderma
Email: lauren.starr@galderma.com
Phone: +41 79 771 52 45

Justine Brodie, Senior Account Manager at OPEN Health
Email: JustineBrodie@OpenHealthGroup.com
Phone: +44 7342 092 035

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Toshiba's Chairperson of the Board of Directors Issues Open Letter to Its Shareholders18.6.2021 12:06:00 EEST | Press release

Toshiba Corporation (TOKYO:6502) today announced that Osamu Nagayama, Chairperson of Toshiba’s Board of Directors, has issued an open letter to the company's shareholders. The full text of the letter is as follows: Dear Shareholders As the Chairperson of the Board of Directors of Toshiba Corporation ("Toshiba", the "Company"), I would like to express my deep regret regarding recent unacceptable events at the Company which have eroded your trust in us. You would have seen that we have already taken decisive and immediate action following the release of the Investigation Report, amending the slate of nominees for directors, committee members and executive officers ahead of the upcoming AGM on June 25. I, together with the Board, am fully committed to ensuring we improve your Company's governance fundamentally and enhance its corporate value. United, we shall be taking the following concrete steps with urgency: In order to stop recurrence, we will conduct an inquiry, with third party part

ISAE-SUPAERO Launches an App to Measure the Climate Impact of Aviation18.6.2021 11:30:00 EEST | Press release

While a referendum to include environmental protection in the Constitution could be held by the end of Emmanuel Macron's five-year term, climate protection initiatives are multiplying. To contribute to the debate, ISAE-SUPAERO is launching CAST: an innovative app that allows everyone to assess the climate impact of aviation by including all phases of the life cycle. A unique app that highlights the real carbon impact of aviation Thomas Planès, a doctoral student at ISAE-SUPAERO, has been working on this project for over a year as part of the CEDAR (*) eco-design research chair. Today, his research has resulted in a modeling tool that takes the form of an open access app. The CAST (Climate and Aviation - Sustainable Trajectories) tool allows anyone to estimate the impact that air transport will have on the climate up to 2050, depending on variables such as traffic volume, fuel consumption per passenger-kilometer, or the decarbonization of the fuel used. In addition to CO2 emissions, it

Ferrari Selects AWS as its Official Cloud Provider to Power Innovation on the Road and Track18.6.2021 09:30:00 EEST | Press release

Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that it has entered into an agreement with Ferrari S.p.A. to become their Official Cloud, Machine Learning, and Artificial Intelligence Provider. Together, the companies will accelerate the pace of innovation across the entire Ferrari organization, including their road cars department, GT Competitions, the Ferrari Challenge, and the Scuderia Ferrari FORMULA 1 (F1) team. Ferrari will use AWS’s breadth and depth of services and proven global infrastructure, including the AWS Europe (Milan) region, to streamline design and testing of its cars, giving customers the most exciting driving experiences possible. In addition, Scuderia Ferrari will leverage AWS to launch a digital fan engagement platform, via its mobile app, to engage hundreds of millions of fans worldwide with exclusive, personalized content. This press release features multimedia. View the full release here: https://www.businesswire.c

MATTR Now Available on Auth0 Marketplace18.6.2021 08:00:00 EEST | Press release

MATTR, a provider of verifiable data and digital trust solutions, today announced the availability of the MATTR VII platform on Auth0 Marketplace, a catalog of trusted technology integrations to extend the functionality of Auth0’s identity management platform. The MATTR VII platform provides an integrated approach to decentralised identity and data ownership. It decouples a user’s identity from their service providers, delivering significant benefits to users and giving builders and developers all the tools they need to create a whole new universe of decentralized products and applications. MATTR VII is composable and configurable to fit developers’ needs, whether it’s a well-established business with legacy systems or a start-up looking to build the next best thing in digital privacy. “MATTR is pleased to partner with Auth0, and welcomes Auth0’s recognition that MATTR’s approach to decentralised identity and data ownership can provide a powerful way to extend and enhance investment al

Bentley Systems Completes Acquisition of Seequent, Global Leader in 3D Modeling Software for the Geosciences17.6.2021 23:05:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the completion of its acquisition of Seequent Holdings Limited, for approximately $900 million in cash (for a debt free business and subject to final working capital adjustments) plus 3,141,342 BSY Class B shares. When announcing its second quarter 2021 operating results (scheduled for August 10, 2021) Bentley Systems will update its full‑year 2021 financial outlook, reflecting the inclusion of Seequent. About Bentley Systems Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry‑leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campus

Pattern Computer Develops Accurate 15-Second COVID-19 Test17.6.2021 23:03:00 EEST | Press release

Pattern Computer,® Inc. (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry. “Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.” Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and spec

Lunaphore Appoints Dr. Carlo Bifulco to Scientific Advisory Board17.6.2021 18:00:00 EEST | Press release

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Dr. Carlo Bifulco, an expert in Translational Molecular Pathology and Pathology Informatics, to its Scientific Advisory Board (SAB) to provide strategic advisory support to the company’s scientific activities and product portfolio development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005459/en/ Dr. Carlo Bifulco (Photo: Business Wire) Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC) and is co-Chair of the SITC Pathology Task convened to establish multiplexed immunohistochemistry/immunofluorescence (mIHC/IF) standards

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom